Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Breast Neoplasms 3Non-melanoma Skin Cancer 2Lung Neoplasms 2Keratosis, Actinic 2Urinary Bladder Neoplasms 1Skin Neoplasms 1Respiratory Aspiration 1Prostatic Hyperplasia 1Pneumothorax 1Pleural Neoplasms 1Pleural Effusion 1Photosensitivity Disorders 1Pain, Postoperative 1Pain 1Neurofibromatosis 1 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Lower Urinary Tract Symptoms 1Hematuria 1Hand-Foot Syndrome 1Empyema, Pleural 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Basal Cell 1

Interventions

Cyclophosphamide 77Dexamethasone 74Melphalan 65Lenalidomide 50Bortezomib 50Peripheral Blood Stem Cell Transplantation 49fludarabine phosphate 47Busulfan 46Filgrastim 39Tacrolimus 37Antilymphocyte Serum 33Radiotherapy 30Mycophenolic Acid 30Thalidomide 28fludarabine 24Methotrexate 22Whole-Body Irradiation 21Cyclosporine 21Calcium Dobesilate 21Granulocyte Colony-Stimulating Factor 18Methylprednisolone 17Etoposide 17Cord Blood Stem Cell Transplantation 14daratumumab 11Prednisone 11Carmustine 11sargramostim 10Stem Cell Transplantation 10Sirolimus 10Rituximab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neoplasms, Plasma Cell × Diclofenac × Clear all
NCT01332617 2017-12-29

Phase II Study of Simvastatin for Relapsed/Refractory Myeloma

University of Louisville

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡